Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in fo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuropsychopharmacology
Glavni autori: Sanacora, Gerard, Johnson, Michael R, Khan, Arif, Atkinson, Sarah D, Riesenberg, Robert R, Schronen, Juan P, Burke, Michael A, Zajecka, John M, Barra, Luis, Su, Hong-Lin, Posener, Joel A, Bui, Khanh H, Quirk, Michael C, Piser, Timothy M, Mathew, Sanjay J, Pathak, Sanjeev
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312066/
https://ncbi.nlm.nih.gov/pubmed/27681442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2016.224
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items